What diseases does Precofu treat? What patients are the indications for Precore?

Proclofor is a highly immunosuppressive drug, and its activity has been confirmed in in vitro and in vivo experiments. Inhibits the production of cytotoxic lymphocytes that are responsible for major transplant rejection. Today let’s take a closer look at what diseases Proximax can treat? What patients are the indications for Precore?

The indications of Precore are as follows:

Prevent graft rejection after liver or kidney transplantation. Treatment of graft rejection that cannot be controlled by other immunosuppressive drugs after liver or kidney transplantation.

Recommendations are as follows:

The actual dose of Proclofor should be adjusted based on the needs of individual patients. The recommended dose is only the starting dose. Therefore, the dose should be adjusted based on clinical judgment and supplemented by monitoring of tacrolimus blood concentration during treatment.

Proximax oral administration: Give the daily dose in two divided doses. It is best to take capsules on an empty stomach or at least 1 hour before or 2-3 hours after eating to achieve maximum absorption. When oral capsules are taken, they usually need to be taken continuously to inhibit transplant rejection, and there is no limit on the treatment period.

Intravenous administration of Puracofu: The concentrated solution for infusion must be diluted with 5% glucose injection or physiological saline in a polyethylene or glass bottle. The concentration of the final infusion solution formed must be in the range of 0.004-0.1 mg/mL. Infuse 20-250 mL over 24 hours. This solution should not be administered in full at one time.

Intravenous therapy should be changed to oral therapy as soon as the patient's condition permits. Intravenous therapy with Preclosumab should not be continued for more than 7 days.

Preclosumab is refractory to conventional immunosuppressive therapy: If rejection occurs in a patient who is refractory to conventional immunosuppressive therapy, Precore® treatment should be initiated at the recommended initial dose for the first immunosuppression in that particular transplant. Concomitant administration of cyclosporine and this drug may prolong the half-life of cyclosporine and produce toxic effects. Treatment with Preclosumab should be initiated after consideration of cyclosporine blood levels and the patient's clinical condition.

In fact, Preclosumab is usually started 12 to 24 hours after stopping administration of cyclosporine. Because cyclosporine clearance may be affected, cyclosporine plasma concentrations should continue to be monitored after dressing changes.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: